AzTrials
AzTrials

CataractNCT07085481

Effect of Warm Bupivacaine on Subtenon Block.

A study testing room temperature Bupivacaine and warm Bupivacaine in people with Cataract, run by Mansoura University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Sub-Tenon's anesthesia is now widely regarded as a preferred local anesthetic method for cataract surgery. Various techniques have been explored to prolong the duration, shorten onset time and improve the efficacy of local anesthetic nerve blocks with varying degrees of success. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Cataract
What is being tested?
room temperature Bupivacaine and warm Bupivacaine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteEgypt
Study dates
1 Oct 2025to 20 Jan 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • American Society of Anesthesiology (ASA) I, II or III patients.
  • Patients scheduled for elective unilateral cataract surgery.

Who cannot join

  • Patient refusal to participate in the study.
  • Altered mental status or un-cooperative patients or psychiatric disorder.
  • History of anesthetic drug allergy.
  • Pre-existing progressive demyelinating neurologic pathology or neuromuscular disorders.
  • Any contraindications to block (as bleeding or coagulation diathesis).

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Mansoura University

    Al Mansurah, 35511

Other trials in Egypt

About this study

Official title: The Influence Of Bupivacaine Temperature On Subtenon Block Characteristics: A Prospective, Randomized, Controlled Trial

Sub-Tenon's anesthesia is now widely regarded as a preferred local anesthetic method for cataract surgery. Various techniques have been explored to prolong the duration, shorten onset time and improve the efficacy of local anesthetic nerve blocks with varying degrees of success. Warming local anesthetic may speed up its onset and prolong its effect by lowering its pKa.The aim of this study is to evaluate the effect of warming bupivacaine on the characteristics of a sub-Tenon's block in patients undergoing cataract surgery. It is hypothesized that warming bupivacaine 0.5% to 37°C will improve the characteristics of sub-Tenon's block. It will prolong the duration of sensory and motor block and accelerate the time onset time of sensory and motor block.

Read the detailed description

Most ophthalmic surgeries are now conducted as day-case procedures under local anesthesia, which has improved efficiency, lowered costs, and enhanced safety, all while ensuring high levels of patient satisfaction. In cataract surgery, local anesthesia is widely favored, as it avoids the risks linked to general anesthesia. Sub-Tenon's anesthesia is now widely regarded as a preferred local anesthetic method for various ophthalmic procedures, especially cataract surgery. Compared to needle-based techniques, it presents several advantages, such as a reduced risk of globe injury, and increased safety for patients taking anticoagulant medications. Nonetheless, minor side effects like chemosis and subconjunctival hemorrhage remain common. When local anesthetic (LA) is delivered into the posterior sub-Tenon's space, it forms a fluid reservoir around the back of the globe, effectively blocking the ciliary nerves and providing anesthesia. Within 3-5 minutes, the anesthetic spreads along the sheaths of the extraocular muscles, diffuses into the intraconal space, and extends to the fascial planes around the eyelids, resulting in akinesia of the globe and orbicularis oculi muscle.The superior oblique muscle is typically the last to become akinetic, likely due to its distance from the globe and the fact that the trochlear nerve lies outside the muscle cone. The volume of LA used for Sub-Tenon's block varies among practitioners, typically ranging from 1 to 10 ml, with most using 2 to 5 ml. Smaller volumes can provide adequate anesthesia but may result in limited akinesia, while larger volumes offer quicker and more complete akinesia but increase the risk of chemosis and elevated intraocular pressure. Various LA agents, including lignocaine, bupivacaine and ropivacaine, have been used, either alone or in combination. A mixture of lignocaine 2% and bupivacaine 0.5% combines the advantages of a rapid block onset by lignocaine and longer effect and postoperative analgesia by bupivacaine, and it is popular among some anesthetists. Adding hyaluronidase can increase membrane permeability, improve the onset and quality of the block and reduce the median effective LA volume needed. A significant constraint of single-shot local anesthetic in the management of peri-operative analgesia is the limited duration of the nerve block. Liposomal bupivacaine was developed to circumvent this, but the duration of action remains controversial, it is expensive and not available in all countries. Various techniques have been explored to prolong the duration, shorten onset time and improve the efficacy of local anesthetic nerve blocks with varying degrees of success. Some of these involve mixing local anesthetics or adding adjuncts.Warming local anesthetic may speed up its onset and prolong its effect by lowering its pKa, thereby increasing the non-ionized fraction responsible for its pharmacological action. This approach has been studied in various regional blocks. However, there is limited research specifically examining the impact of warmed anesthetic on injection pain during ophthalmic blocks.

The aim of this study:

evaluate the effect of warming bupivacaine on the characteristics of a sub-Tenon's block in patients undergoing cataract surgery.

Sample Size Calculation:

Sample size was calculated using Power Analysis and Sample Size software program (PASS) version 3.1.9.2 for windows (2017). The primary outcome will be time to onset of sensory block. In a pilot study performed on 10 patients using room temperature bupivacaine, the mean (SD) of time to onset of sensory block was 8(3) minutes. Using a two-sided hypothesis test with a significance level of 0.05, assuming alpha = 0.05 and beta = 0.2 (power = 80%) and using a student t test, 57 subjects will be required in each group to detect 20 % difference between groups which is considered the minimal clinically important difference. To allow for subject dropouts, 60 subjects will be assigned to each group.

The study will be conducted in Mansoura ophthalmology center including 120 patients who will be scheduled for cataract surgery under local anesthesia. eligible patients will be randomly assigned to 2 equal groups (operating room temperature group) and (warm temperature group) according to computer-generated table of random numbers. The group allocation will be concealed in sequentially numbered, sealed opaque envelopes which will be opened only after obtaining the written informed consent.

All patients will be kept fasting according to pre-operative ASA recommendations prior to surgery. Basic demographic characters including age, gender, and BMI will be recorded.

The peri-operative management will be identical in both groups. All patients with planned day case cataract surgery under sub-Tenon's anesthesia will be assessed preoperatively by detailed medical history taking and physical examination. Investigations will be requested as appropriate. The 11-point NRS score (0 = no pain and 10 = the worst possible pain) will be explained to each patient.

On arrival to the anesthetic room, standard monitoring including 3 leads electrocardiogram (ECG), pulse oximetry, and noninvasive blood pressure will be applied. Baseline vital signs (heart rate and mean arterial blood pressure) will be recorded. Intravenous access will be established, and all patients will receive a single dose of prophylactic antibiotic after sensitivity test. No sedation will be administered A standardized sub-Tenon's block will be employed by the same consultant anesthetist to all patients within the study. The surface of the eye will be cleaned with two drops of 5% povidine iodine. The eyelids and orbital rim will be cleaned with 10% povidine iodine and an eye speculum will be inserted. A small incision will be made 5 mm from the limbus in the inferior-nasal quadrant. Blunt dissection will be used to identify the sub-Tenon's space. Once identified, a 19-G sub-Tenon's needle will be inserted, and the local anesthetic solution will be given slowly over 20 s. At no point during the administration of the injection the barrel of the syringe will be handled by consultant anesthetist.

Statistical Methods:

The collected data will be coded, processed, and analyzed using SPSS program (version 22) for Windows. Normality of numerical data distribution will be tested by Shapiro-Wilk test. Continuous data of normal distribution will be presented as mean ± SD and will be compared with the unpaired student's t test. Non-normally distributed data will be presented as median (range) and will be compared with the Mann-Whitney U test. Categorical data will be presented as number (percentage) and will be compared with the Chi-square test. All data will be considered statistically significant if P value is ≤ 0.05.

Conditions
Cataract
Being tested
room temperature Bupivacaine, warm Bupivacaine
Keywords
sub tenon, bupivacaine, sensory block, temperature
Medical subject headings
Cataract

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • room temperature BupivacaineDrug

    Also called Non-warmed bupivacaine

    bupivacaine will be on a sterile shelf in the operating room at 23°C. The empty syringes and needles will be also on the same shelf before their use.

  • warm BupivacaineDrug

    Also called Pre-heated bupivacaine

    bupivacaine will be warmed to 37◦C for 20 minutes. The empty syringes and needles, in their packaging, will be held at the same temperature for at least 2 hours before initiating the block.

Study groups in NCT07085481
Study groupRoleWhat they receive
Operating room temperature bupivacaineExperimentalpatients will receive local anesthetic (5ml containing 5mg bupivacaine) that will be on a sterile shelf in the operating room at 23°C. The empty syringes and needles will be also on the same shelf before their use.
Receives: Drug: room temperature Bupivacaine
Warm bupivacaineExperimentalpatients will receive local anesthetic (5ml containing 5mg bupivacaine) warmed to 37◦C for 20 minutes. The empty syringes and needles, in their packaging, will be held at the same temperature for at least 2 hours before initiating the block.
Receives: Drug: warm Bupivacaine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. the time to onset of sensory block

    Sensory block (loss of sensation in the conjunctiva and sclera and indirectly optic nerve block) will be evaluated by touch the conjunctiva using cotton wisp or forceps in the inferior fornix and ask patient if they feel it, on a 3-point scale 0= No sensation (complete block) 1= reduction in sensation 2= on loss of sensation (no block), with identical contralateral testing as reference. Ask about vision or light perception; if the optic nerve is partially blocked, the patient may report blurred or lost vision- full optic nerve block causes temporary vision loss. The time to sensory block onset (the time elapsed from the end of injection and start of the loss of sensation score =1)

    Measured: Sensory blockade will be evaluated at 1, 2, 4, 6, 8, 10 and 15 minutes after injection, and then every 30 minutes after the end of surgery for 6 hours and end of block duration is defined by return of sensation.

Secondary outcomes (9)
  1. time to complete sensory block

    Sensory block (loss of sensation in the conjunctiva and sclera and indirectly optic nerve block) will be evaluated by touch the conjunctiva using cotton wisp or forceps in the inferior fornix and ask patient if they feel it, on a 3-point scale 0= No sensation (complete block) 1= reduction in sensation 2= on loss of sensation (no block), with identical contralateral testing as reference. Ask about vision or light perception; if the optic nerve is partially blocked, the patient may report blurred or lost vision- full optic nerve block causes temporary vision loss. time to complete sensory block(score = 0),

    Measured: Sensory blockade will be evaluated at 1, 2, 4, 6, 8, 10 and 15 minutes after injection, and then every 30 minutes after the end of surgery for 6 hours and end of block duration is defined by return of sensation

  2. duration of sensory block

    Sensory block (loss of sensation in the conjunctiva and sclera and indirectly optic nerve block) will be evaluated by touch the conjunctiva using cotton wisp or forceps in the inferior fornix and ask patient if they feel it, on a 3-point scale 0= No sensation (complete block) 1= reduction in sensation 2= on loss of sensation (no block), with identical contralateral testing as reference. Ask about vision or light perception; if the optic nerve is partially blocked, the patient may report blurred or lost vision- full optic nerve block causes temporary vision loss. duration of sensory block (defined as the elapsed time between the end of injection and the complete resolution and recovery to a normal sensory function)

    Measured: Sensory blockade will be evaluated at 1, 2, 4, 6, 8, 10 and 15 minutes after injection, and then every 30 minutes after the end of surgery for 6 hours and end of block duration is defined by return of sensation

  3. The time to motor block onset

    Motor block (ocular akinesia) will be assessed by asking the patient to move the eye in the four cardinal directions; up ( superior rectus), down (inferior rectus), medially(medial rectus) , and laterally (lateral rectus) using Brahma score (0-3 for each direction) 0= No movement ( complete block) 1= marked reduction in movement 2= slight reduction in movement 3= full movement (no block), total maximum score= 12.The time to motor block onset (score = 8)

    Measured: motor blockade will be evaluated at 1, 2, 4, 6, 8, 10 and 15 minutes after injection, and then every 30 minutes after the end of surgery for 6 hours

  4. time to complete motor block

    Motor block (ocular akinesia) will be assessed by asking the patient to move the eye in the four cardinal directions; up ( superior rectus), down (inferior rectus), medially(medial rectus) , and laterally (lateral rectus) using Brahma score (0-3 for each direction) 0= No movement ( complete block) 1= marked reduction in movement 2= slight reduction in movement 3= full movement (no block), total maximum score= 12.time to complete motor block (score=0)

    Measured: motor blockade will be evaluated at 1, 2, 4, 6, 8, 10 and 15 minutes after injection, and then every 30 minutes after the end of surgery for 6 hours

  5. duration of motor block

    Motor block (ocular akinesia) will be assessed by asking the patient to move the eye in the four cardinal directions; up ( superior rectus), down (inferior rectus), medially(medial rectus) , and laterally (lateral rectus) using Brahma score (0-3 for each direction) 0= No movement ( complete block) 1= marked reduction in movement 2= slight reduction in movement 3= full movement (no block), total maximum score= 12.duration of motor block (defined as the elapsed time between the end of injection and the complete resolution of motor block)

    Measured: motor blockade will be evaluated at 1, 2, 4, 6, 8, 10 and 15 minutes after injection, and then every 30 minutes after the end of surgery for 6 hours

  6. Pain during injection

    Pain during injection will be assessed using the 11-point NRS score (0 = no pain and 10 = the worst possible pain).

    Measured: during injection only

  7. Patient satisfaction

    using a 4-point scale (1 = excellent,2= good, 3 = fair and 4 = poor).

    Measured: before discharge only

  8. surgeon satisfaction

    using a 4-point scale (1 = excellent,2= good, 3 = fair and 4 = poor).

    Measured: at the end of the surgery

  9. Incidence of adverse effects

    hypotension and bradycardia

    Measured: Up to 6 hours after the procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jul 2025
  2. Study start1 Oct 2025
  3. Primary completion30 Dec 2025
  4. Study completion20 Jan 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Prospective, randomized, double blind study
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
120 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07085481
Sponsor's protocol ID
Warm Bupivacaine for eye block
Status last verified
Jan 2026
First submitted
18 Jul 2025
Last updated
27 Jan 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing room temperature Bupivacaine and warm Bupivacaine in people with Cataract, run by Mansoura University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

the time to onset of sensory block (time frame: Sensory blockade will be evaluated at 1, 2, 4, 6, 8, 10 and 15 minutes after injection, and then every 30 minutes after the end of surgery for 6 hours and end of block duration is defined by return of sensation.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in